Patheon NV Company Profile (NASDAQ:PTHN)

About Patheon NV (NASDAQ:PTHN)

Patheon NV logoPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTHN
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $5.01 billion
  • Outstanding Shares: 145,136,000
Average Prices:
  • 50 Day Moving Avg: $28.60
  • 200 Day Moving Avg: $28.56
  • 52 Week Range: $23.72 - $34.84
P/E:
  • Trailing P/E Ratio: 56.09
  • Foreward P/E Ratio: 23.19
  • P/E Growth: 1.57
Sales & Book Value:
  • Annual Revenue: $1.92 billion
  • Price / Sales: 2.61
  • Book Value: ($2.11) per share
  • Price / Book: -16.37
Profitability:
  • EBIDTA: $359.6 million
Misc:
  • Average Volume: 1.41 million shs.
  • Short Ratio: 5.95
 

Frequently Asked Questions for Patheon NV (NASDAQ:PTHN)

What is Patheon NV's stock symbol?

Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."

How were Patheon NV's earnings last quarter?

Patheon NV (NASDAQ:PTHN) released its quarterly earnings data on Thursday, March, 16th. The company reported $0.14 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.08. The business earned $457.40 million during the quarter, compared to analyst estimates of $463.39 million. The business's revenue was up 12.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.08) EPS. View Patheon NV's Earnings History.

Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?

12 analysts have issued twelve-month target prices for Patheon NV's stock. Their forecasts range from $28.00 to $35.00. On average, they anticipate Patheon NV's stock price to reach $31.80 in the next twelve months. View Analyst Ratings for Patheon NV.

What are analysts saying about Patheon NV stock?

Here are some recent quotes from research analysts about Patheon NV stock:

  • 1. According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (5/19/2017)
  • 2. Jefferies Group LLC analysts commented, "PTHN's results are a further indication of inherent volatility in the CMO business despite long-cycle contracts. FY17 guidance was reduced on FX headwinds and project delays partially offset by the Roche facility acquisition. LT indicators were more positive and we still believe PTHN can generate above industry growth." (3/17/2017)
  • 3. Morgan Stanley analysts commented, "High operating leverage can drive ~330 bps in EBITDA margin expansion by FY18; we see EPS growth of 58 percent/20 percent in FY17/FY18," analyst Ricky Goldwasser wrote in a note.Goldwasser said the company is poised to expand its CMO share due to its open platform, end-to-end service, quality and global footprint.Related Link: Wells Fargo Initiates Coverage On Patheon At OutperformForward ViewAs such, the analyst believes Patheon can grow its top line at an 11 percent/8 percent CAGR in FY17/FY18, above market growth rates of 5–6 percent, with 209 bps and 121 bps in EBITDA margin expansion in FY17/FY18. The analyst estimates Patheon can grow EBITDA margins from 21.6 percent in FY16 to 24.8 percent in FY18."Patheon is poised to thrive on biologics, the fastest growing area in drug development, given capabilities that span formulation / development as well as API," (8/15/2016)

Who are some of Patheon NV's key competitors?

Who are Patheon NV's key executives?

Patheon NV's management team includes the folowing people:

  • Paul S. Levy, Chairman of the Board
  • James C. Mullen, Chief Executive Officer, Director
  • Stuart R. Grant, Chief Financial Officer, Executive Vice President
  • Gilles A. Cottier, President - Global Pharmaceutical Development Services
  • Franco Negron, President - Drug Product Services
  • Lukas Utiger, President - Drug Substance
  • Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
  • Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
  • Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
  • Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement

When did Patheon NV IPO?

(PTHN) raised $625 million in an initial public offering (IPO) on Thursday, July 21st 2016. The company issued 30,500,000 shares at $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities served as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

Who owns Patheon NV stock?

Patheon NV's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JLL ASSOCIATES G.P. V (PATHEON), LTD. (43.10%), Wellington Management Group LLP (3.17%), JPMorgan Chase & Co. (2.53%), TimesSquare Capital Management LLC (1.34%), Ameriprise Financial Inc. (1.24%) and Eagle Asset Management Inc. (0.85%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Institutional Ownership Trends for Patheon NV.

Who sold Patheon NV stock? Who is selling Patheon NV stock?

Patheon NV's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Acadian Asset Management LLC, Janus Capital Management LLC, Columbus Circle Investors, TIAA CREF Investment Management LLC, American Century Companies Inc., Pier Capital LLC and BlueMar Capital Management LLC. View Insider Buying and Selling for Patheon NV.

Who bought Patheon NV stock? Who is buying Patheon NV stock?

Patheon NV's stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, OppenheimerFunds Inc., Ameriprise Financial Inc., Schroder Investment Management Group, Redmile Group LLC, Zweig DiMenna Associates LLC, MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. Company insiders that have bought Patheon NV stock in the last two years include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Insider Buying and Selling for Patheon NV.

How do I buy Patheon NV stock?

Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Patheon NV's stock price today?

One share of Patheon NV stock can currently be purchased for approximately $34.55.


MarketBeat Community Rating for Patheon NV (NASDAQ PTHN)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Patheon NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Patheon NV (NASDAQ:PTHN) (?)
Ratings Breakdown: 5 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $31.80 (7.96% downside)

Analysts' Ratings History for Patheon NV (NASDAQ:PTHN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Jefferies Group LLCDowngradeBuy -> Hold$32.00 -> $35.00LowView Rating Details
5/15/2017Evercore ISIDowngradeOutperform$35.00LowView Rating Details
5/15/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/15/2017Piper Jaffray CompaniesDowngradeOverweight -> NeutralLowView Rating Details
3/17/2017Robert W. BairdDowngradeOutperform -> Neutral$34.00 -> $28.00LowView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$31.00N/AView Rating Details
8/16/2016Credit Suisse Group AGInitiated CoverageNeutral$30.00N/AView Rating Details
8/15/2016Raymond James Financial, Inc.Initiated CoverageOutperform$32.50N/AView Rating Details
8/15/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00N/AView Rating Details
8/15/2016KeyCorpInitiated CoverageOverweight$33.00N/AView Rating Details
8/15/2016JPMorgan Chase & Co.Initiated CoverageOverweight$30.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Patheon NV (NASDAQ:PTHN)
Earnings by Quarter for Patheon NV (NASDAQ:PTHN)
Earnings History by Quarter for Patheon NV (NASDAQ PTHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/20171/31/2017$0.22$0.14$463.39 million$457.40 millionViewN/AView Earnings Details
12/20/2016Q416$0.39$0.30$496.27 million$510.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Patheon NV (NASDAQ:PTHN)
2017 EPS Consensus Estimate: $1.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.19$0.22$0.21
Q2 20172$0.29$0.37$0.33
Q3 20171$0.38$0.38$0.38
Q4 20172$0.42$0.46$0.44
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Patheon NV (NASDAQ:PTHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2016Paul S LevyDirectorBuy10,000$29.55$295,500.00View SEC Filing  
9/28/2016Paul S LevyDirectorBuy15,000$29.64$444,600.00View SEC Filing  
9/12/2016Paul S LevyDirectorBuy37,000$28.01$1,036,370.00View SEC Filing  
7/26/2016Jll Patheon Co-Investment FundMajor ShareholderBuy815,730$19.85$16,192,240.50View SEC Filing  
7/26/2016Pamela DaleyDirectorBuy48,800$19.85$968,680.00View SEC Filing  
7/21/2016Philip EykermanDirectorBuy28,000$25.00$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Patheon NV (NASDAQ:PTHN)
Latest Headlines for Patheon NV (NASDAQ:PTHN)
Source:
DateHeadline
americanbankingnews.com logoPatheon NV (PTHN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 6:20 PM
americanbankingnews.com logoPatheon NV (PTHN) Expected to Announce Quarterly Sales of $465.97 Million
www.americanbankingnews.com - May 21 at 6:36 PM
finance.yahoo.com logoRoyal DSM N.V. -- Moody's changes Royal DSM's outlook to stable from negative; affirms A3/P-2 ratings
finance.yahoo.com - May 19 at 12:13 PM
americanbankingnews.com logoPatheon NV (PTHN) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 19 at 7:32 AM
finance.yahoo.com logoPatheon Holdings I B.V. -- Moody's places ratings of Patheon Holdings I B.V. on review for upgrade
finance.yahoo.com - May 17 at 7:18 PM
finance.yahoo.com logoNBPE Announces Valuation Uplift Following the Announced Acquisition of Patheon
finance.yahoo.com - May 17 at 8:22 AM
americanbankingnews.com logoPatheon NV (PTHN) Downgraded by Jefferies Group LLC to Hold
www.americanbankingnews.com - May 16 at 10:04 PM
finance.yahoo.com logoPatheon NV breached its 50 day moving average in a Bullish Manner : PTHN-US : May 16, 2017
finance.yahoo.com - May 16 at 7:04 PM
finance.yahoo.com logoThermo Fisher Scientific (Finance I) B.V. -- Moody's affirms Thermo Fisher Scientific's Baa2 senior unsecured rating following Patheon acquisition announcement
finance.yahoo.com - May 16 at 7:03 PM
nasdaq.com logoPTHN Crosses Above Average Analyst Target
www.nasdaq.com - May 16 at 9:44 AM
americanbankingnews.com logoPatheon NV (PTHN) Expected to Announce Earnings of $0.16 Per Share
www.americanbankingnews.com - May 16 at 9:20 AM
streetinsider.com logoS&P 500, Nasdaq Composite hit record-highs
www.streetinsider.com - May 15 at 6:36 PM
reuters.com logoThermo Fisher to buy Patheon for $5.2 billion to expand biopharma services
www.reuters.com - May 15 at 6:36 PM
americanbankingnews.com logoPiper Jaffray Companies Lowers Patheon NV (PTHN) to Neutral
www.americanbankingnews.com - May 15 at 5:02 PM
americanbankingnews.com logoPatheon NV (PTHN) Stock Rating Lowered by William Blair
www.americanbankingnews.com - May 15 at 5:02 PM
americanbankingnews.com logoPatheon NV (PTHN) Downgraded by Evercore ISI
www.americanbankingnews.com - May 15 at 4:28 PM
finance.yahoo.com logoThermo Fisher Extends Binge With $5.2 Billion Patheon Deal
finance.yahoo.com - May 15 at 9:45 AM
finance.yahoo.com logoThermo Fisher to buy Patheon in $5.2 billion deal
finance.yahoo.com - May 15 at 9:45 AM
finance.yahoo.com logoPatheon Completes Sterile Expansion Project at Greenville, NC Manufacturing Site
finance.yahoo.com - May 8 at 11:55 AM
americanbankingnews.com logoPatheon NV (PTHN) Expected to Announce Quarterly Sales of $465.92 Million
www.americanbankingnews.com - April 27 at 12:20 PM
americanbankingnews.com logoPatheon NV (PTHN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 5:51 PM
americanbankingnews.com logoZacks: Analysts Anticipate Patheon NV (PTHN) to Announce $0.16 Earnings Per Share
www.americanbankingnews.com - April 25 at 2:15 PM
finance.yahoo.com logoDPx Holdings B.V. -- Moody's assigns B2 to DPx Holding's term loan following repricing
finance.yahoo.com - April 14 at 6:57 PM
americanbankingnews.com logoPatheon NV (PTHN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 31 at 1:11 PM
finance.yahoo.com logoPatheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard
finance.yahoo.com - March 30 at 7:38 PM
americanbankingnews.com logoPatheon NV (PTHN) Downgraded by Zacks Investment Research to "Strong Sell"
www.americanbankingnews.com - March 28 at 8:10 AM
americanbankingnews.com logoPatheon NV (PTHN) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - March 22 at 6:01 PM
us.rd.yahoo.com logoPatheon N.V. downgraded by KeyBanc Capital Mkts and Robert W. Baird
us.rd.yahoo.com - March 18 at 12:31 AM
americanbankingnews.com logoPatheon NV (PTHN) Cut to “Neutral” at Robert W. Baird
www.americanbankingnews.com - March 17 at 7:34 PM
investopedia.com logoPatheon 1Q Earnings Missed Street Estimates (PTHN)
www.investopedia.com - March 17 at 7:31 PM
americanbankingnews.com logoPatheon NV’s (PTHN) “Buy” Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - March 17 at 5:42 PM
us.rd.yahoo.com logoPatheon 1Q Earnings Missed Analyst Estimates
us.rd.yahoo.com - March 16 at 8:08 PM
finance.yahoo.com logoEdited Transcript of PTHN earnings conference call or presentation 16-Mar-17 12:00pm GMT
finance.yahoo.com - March 16 at 8:08 PM
americanbankingnews.com logoPatheon NV (PTHN) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
us.rd.yahoo.com logoPatheon Reports Fiscal 2017 First Quarter Results
us.rd.yahoo.com - March 16 at 8:24 AM
us.rd.yahoo.com logo6:36 am Patheon N.V. misses by $0.08, misses on revs; lowers FY17 guidance
us.rd.yahoo.com - March 16 at 8:24 AM
sg.finance.yahoo.com logoPatheon Holdings misses Street 1Q forecasts
us.rd.yahoo.com - March 16 at 8:24 AM
biz.yahoo.com logoQ1 2017 Patheon NV Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 8:24 AM
americanbankingnews.com logoPatheon NV (PTHN) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 15 at 8:19 AM
finance.yahoo.com logoPatheon to Announce First Quarter Fiscal Year 2017 Financial Results on March 16, 2017
finance.yahoo.com - March 3 at 8:33 AM
finance.yahoo.com logoPatheon Named Supply Chain Resiliency Partner of the Year
finance.yahoo.com - March 2 at 7:30 PM
nasdaq.com logoPatheon Reaches Analyst Target Price
www.nasdaq.com - February 24 at 8:34 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statemen
biz.yahoo.com - February 8 at 9:27 PM
finance.yahoo.com logoCORRECTING and REPLACING PHOTO Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site
finance.yahoo.com - February 1 at 10:08 PM
finance.yahoo.com logoPatheon to Participate in the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 3:18 PM
thestreet.com logoInsiders Will Likely Move Pharmaceutical Company Patheon's Stock
www.thestreet.com - December 30 at 7:42 PM
finance.yahoo.com logoPATHEON N.V. Financials
finance.yahoo.com - December 29 at 7:22 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 10-K, Annual Report
biz.yahoo.com - December 23 at 7:31 PM
finance.yahoo.com logoEdited Transcript of PTHN earnings conference call or presentation 20-Dec-16 1:00pm GMT
finance.yahoo.com - December 21 at 12:03 AM
publicnow.com logoPatheon Reports Growth Across All Segments For Fourth Quarter; Provides Outlook for Fiscal Year 2017
us.rd.yahoo.com - December 20 at 2:00 PM

Social

Chart

Patheon NV (PTHN) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff